Drug Comparison
Tirzepatide vs CagriSema: Complete Comparison
If you're weighing Tirzepatide versus CagriSema, you're asking one of the most common questions in obesity medicine today. Here is a rigorous, data-driven breakdown of every dimension that matters — mechanism, efficacy, dosing, side effects, cost, and FDA status.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
Weight Loss
CagriSema
22.7% vs 22.5%
Lower Cash Cost
Tirzepatide
$1,086/mo vs $9,999/mo
Dosing
Tirzepatide
Weekly vs Weekly
FDA Status
Approved 2023
Phase 3
Side-by-Side Comparison Table
| Feature | Tirzepatide | CagriSema |
|---|---|---|
| Brand Name(s) | Mounjaro, Zepbound | Cagrilintide + Semaglutide (combination) |
| Mechanism | GIP/GLP-1 dual receptor agonist | GLP-1 receptor agonist + Amylin analog (cagrilintide) |
| FDA Status | Approved 2023 | Phase 3 |
| Mean Weight Loss | 22.5% (SURMOUNT-1) | 22.7% (REDEFINE-1) |
| Starting Dose | 2.5 mg | 0.25 mg |
| Max Dose | 15 mg | 2.4 mg |
| Frequency | Weekly | Weekly |
| Half-Life | 120 hrs | 168 hrs |
| Cash Price/Month | $1086 | N/A (investigational) |
| Prior Auth Required | Yes | No |
| Key Pivotal Trial | SURMOUNT-1 | REDEFINE-1 |
Weight Loss Efficacy: Tirzepatide vs CagriSema
In their respective pivotal trials, Tirzepatide achieved a mean weight loss of 22.5% (SURMOUNT-1) while CagriSema achieved 22.7% (REDEFINE-1). This 0.2 percentage point difference is relatively modest, though direct head-to-head trial data between these specific agents may be limited.
Important caveat: These trials enrolled different populations (different BMI criteria, T2D vs non-diabetic, different geographies) and used different primary endpoints. Direct comparisons should be interpreted with caution.
Mechanism: How They Work Differently
Tirzepatide is a GIP/GLP-1 dual receptor agonist. CagriSema is a GLP-1 receptor agonist + Amylin analog (cagrilintide). Both medications work through the GLP-1 pathway but differ in their additional receptor targets, half-lives, and molecular structures.
Side Effects
Both Tirzepatide and CagriSema share a similar GI side effect profile. Common side effects for both include: constipation, diarrhea, fatigue, injection-site reaction. These are typically most pronounced during dose escalation and improve with time.
Tirzepatide-specific: abdominal pain. CagriSema-specific: headache
Cost Comparison
Cash pay prices vary significantly: Tirzepatide lists at approximately $1086/month vs CagriSema at N/A (not commercially available). Both require prior authorization through most commercial insurers.
Which Is Right for You? Decision Guide
Consider Tirzepatide if:
- ✓ Your insurance specifically covers Mounjaro
- ✓ Your prescriber has experience with Tirzepatide
- ✓ Once-weekly injection fits your schedule
- ✓ You have prior experience with GIP agonists
Consider CagriSema if:
- ✓ Your insurance specifically covers Cagrilintide + Semaglutide (combination)
- ✓ Higher weight loss efficacy is your primary goal
- ✓ Once-weekly injection is preferred
- ✓ Simpler GLP-1 only mechanism is preferred
Bottom line: The choice between Tirzepatide and CagriSema is best made with your prescribing clinician, accounting for your specific medical history, insurance coverage, prior treatment response, and metabolic goals. Neither medication is universally superior for all patients.